(VIANEWS) – Genmab (GMAB), StoneCastle Financial Corp (BANX), Playa Hotels & Resorts N.V. (PLYA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Genmab (GMAB)
56.6% sales growth and 23.59% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.66.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 57.96. Meaning, the purchaser of the share is investing $57.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.59%.
Sales Growth
Genmab’s sales growth is 65.7% for the ongoing quarter and 56.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1800% and 1263.6%, respectively.
Yearly Top and Bottom Value
Genmab’s stock is valued at $38.32 at 16:22 EST, way below its 52-week high of $47.50 and way higher than its 52-week low of $26.19.
2. StoneCastle Financial Corp (BANX)
37.9% sales growth and 3.56% return on equity
ArrowMark Financial Corp. is a closed-end balanced mutual fund launched and managed by ArrowMark Asset Management, LLC. It invests in public equity and fixed income markets of global region. For its equity portion, the fund invests in stocks of companies operating across financials, banks sectors. It invests in growth and value stocks of companies across diversified market capitalization. For its fixed income portion, the fund invests in debt and subordinated debt, structured notes and securities, regulatory capital securities which are rated below investment grade. ArrowMark Financial Corp. was formed on February 7, 2013 and is domiciled in the United States.
Earnings Per Share
As for profitability, StoneCastle Financial Corp has a trailing twelve months EPS of $0.8.
PE Ratio
StoneCastle Financial Corp has a trailing twelve months price to earnings ratio of 22.5. Meaning, the purchaser of the share is investing $22.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.56%.
Yearly Top and Bottom Value
StoneCastle Financial Corp’s stock is valued at $18.00 at 16:22 EST, way under its 52-week high of $21.94 and way higher than its 52-week low of $15.20.
Revenue Growth
Year-on-year quarterly revenue growth grew by 42.4%, now sitting on 21.53M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 29.3% and 35.7%, respectively.
3. Playa Hotels & Resorts N.V. (PLYA)
29.9% sales growth and 8.75% return on equity
Playa Hotels & Resorts N.V., together with its subsidiaries, owns, develops, and operates resorts in prime beachfront locations in Mexico and the Caribbean. As of December 31, 2021, it owned a portfolio of 22 resorts with 8,366 rooms located in Mexico, Jamaica, and the Dominican Republic. The company was founded in 2006 and is headquartered in Fairfax, Virginia.
Earnings Per Share
As for profitability, Playa Hotels & Resorts N.V. has a trailing twelve months EPS of $0.34.
PE Ratio
Playa Hotels & Resorts N.V. has a trailing twelve months price to earnings ratio of 25.82. Meaning, the purchaser of the share is investing $25.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.75%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.8%, now sitting on 846.56M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Playa Hotels & Resorts N.V.’s EBITDA is 2.51.
4. Afya (AFYA)
9% sales growth and 11.9% return on equity
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
Earnings Per Share
As for profitability, Afya has a trailing twelve months EPS of $0.44.
PE Ratio
Afya has a trailing twelve months price to earnings ratio of 24.25. Meaning, the purchaser of the share is investing $24.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.9%.
Yearly Top and Bottom Value
Afya’s stock is valued at $10.62 at 16:22 EST, way under its 52-week high of $17.02 and way higher than its 52-week low of $8.73.
Sales Growth
Afya’s sales growth is 25.2% for the ongoing quarter and 9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 2.24B for the twelve trailing months.
Moving Average
Afya’s value is way below its 50-day moving average of $12.70 and way under its 200-day moving average of $13.13.
